🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If applying for this award even crosses your mind, then just do it! It's helped this lot fly: 2024 Sabela Lens García Liver Growth and Cancer Lab 2023 David James Pinato 🇺🇦 loeymak 2022 Salvatore Piano M. Perugorria 2021 Charlotte Scott Q. Pan 2020 Thomas Reiberger Prakash Ramachandran 2019 Virginia Martin Guilliams

Proud to see @chrisjmwilliams chairing an impactful colorectal cancer session at #ESMO2024

Can we think of curative approaches in unresectable HCC? My take on #HCC multimodal care at #ASCOMOS in Penang, Malaysia UPO - Università Surgery and Cancer

Toronto welcomes #LiverLovers ILCA for a few days of science 🧪 clinical practice 🧑‍⚕️ and networking 🗣️ #ILCA2024

#BrunoSangro ILCA #ILCA2024 goals & endpoints in liver cancer care

BTC Management in the molecular era chiara braconi ILCA #ILCA24

I am honoured to receive the prestigious Young Investigator Award by ILCA ! So grateful to my extraordinary mentors for having always supported me 🩺 Lorenza Rimassa David James Pinato 🇺🇦 Stay tuned for my presentation on pathological response in HCC tomorrow at #ILCA24 💊

Congrats to all ILCA Junior Investigator Awardee at #ILCA24

“Not your average resident” - he said Antonio D'Alessio and he was right 🥳 ILCA Surgery and Cancer #ILCA24 #JuniorInvestigatorAward

I’ll take it as a compliment 😉 🤵‍♂️ ILCA Surgery and Cancer UPO - Università #ILCA24

Presenting at #ILCA24 & published Online First: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with #hepatocellularcarcinoma: a cross-trial, patient-level analysis #livercancer Antonio D'Alessio David James Pinato 🇺🇦 thelancet.com/journals/lanon…

Just out on the The Lancet Oncology : our NeoHCC Study 🗞️ 📈 Path response after neoadj ICI predicts for RFS in HCC 🔥 HR 0.26 for RFS improvement with MPR 📊 30% of MPR is not predicted by ORR using RECIST 1.1 🎯 90% regression is the best threshold for RFS David James Pinato 🇺🇦 ILCA

Have you finally found a predictive biomarker, in #HCC 🔥 Antonio D'Alessio ? 🔬 ILCA Surgery and Cancer #ILCA24 ESMO - Eur. Oncology ASCO thelancet.com/journals/lanon…

Pathological response following neoadjuvant immune checkpoint inhibitors in HCC: a cross-trial, patient-level analysis The Lancet Oncology doi.org/10.1016/S1470-… 👉111 pts, 1.4 mo neoadj. 💊 👉MPR: 32%, PCR 18% 👉Best threshold 90% 🧐Neoadj ICI is the way to go ILCA EASL Education

I will soon be abandoning X I don’t want my content to go to the profit of those who don’t care for the benefit of humanity bsky.app/profile/djpina…

David James Pinato 🇺🇦 discussing systemic therapeutic options for patients with #HCC at #ESMOAsia24 in #Singapore ESMO - Eur. Oncology

Patient advocate sharing patients’ preferences, goals, and values (not necessarily in this order) about (but not only) subcutaneous vs iv immunotherapy in #HCC and #NSCLC at #ESMOAsia24 in #Singapore ESMO - Eur. Oncology David James Pinato 🇺🇦 toh han chong

Wonderful news - Conquer Cancer, the ASCO Foundation has chosen our work on neoadj ICI in HCC for the 2025 ASCO GI Merit Award🏅Pathological or radiological response as best RFS predictor? See you at my poster next Friday in San Francisco ! David James Pinato 🇺🇦 Surgery and Cancer ASCO conquer.org/news/conquer-c…

I will soon be deactivating my X profile If you would like to stay in touch professionally and personally follow me on BlueSky bluesky bsky.app/profile/djpina…

Very proud of Pasquale Lombardi for his 🥇 Best Poster Prize at ESMO - Eur. Oncology #ESMOGI25 Imperial College London Surgery and Cancer